(4-bromophenyl)(pyridin-3-yl)acetonitrile | 892408-86-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-bromophenyl)(pyridin-3-yl)acetonitrile
• 英文别名: (4-bromo-phenyl)-pyridin-3-yl-acetonitrile；2-(4-Bromophenyl)-2-pyridin-3-ylacetonitrile
• CAS: 892408-86-5
• 化学式: C₁₃H₉BrN₂
• 分子量: 273.132
• InChiKey: JSVXWEAOIUYNSM-UHFFFAOYSA-N

物化性质

• 沸点：
  408.6±35.0 °C(Predicted)
• 密度：
  1.446±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4-bromophenyl)(pyridin-3-yl)acetonitrile 在 水 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 2-(4-bromophenyl)-2-(pyridin-3-yl)-1-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]ethanone
  参考文献：
  名称：

  Two Analogues of Fenarimol Show Curative Activity in an Experimental Model of Chagas Disease

  摘要：

  Chagas disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), is an increasing threat to global health. Available medicines were introduced over 40 years ago, have undesirable side effects, and give equivocal results of cure in the chronic stage of the disease. We report the development of two compounds, 6 and (S)-7, with PCR-confirmed curative activity in a mouse model of established T. cruzi infection after once daily oral dosing for 20 days at 20 mg/kg 6 and 10 mg/kg (S)-7. Compounds 6 and (S)-7 have potent in vitro activity, are noncytotoxic, show no adverse effects in vivo following repeat dosing, are prepared by a short synthetic route, and have druglike properties suitable for preclinical development.

  DOI：

  10.1021/jm401610c
• 作为产物：
  描述：

  3-氟吡啶 、 对溴苯乙腈 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 16.33h， 以39%的产率得到(4-bromophenyl)(pyridin-3-yl)acetonitrile
  参考文献：
  名称：

  WO2006/66197

  摘要：

  公开号：

文献信息

• Tetrahydroisoquinoline compounds
  申请人：Carruthers I. Nicholas

  公开号：US20060194837A1

  公开（公告）日：2006-08-31

  Certain tetrahydroisoquinoline compounds are histamine H 3 receptor and serotonin transporter modulators useful in the treatment of histamine H 3 receptor- and serotonin-mediated diseases.

  某些四氢异喹啉化合物是组胺H3受体和血清素转运体调节剂，可用于治疗组胺H3受体和血清素介导的疾病。
• TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS
  申请人：Janssen Pharmaceutica NV

  公开号：EP1831173B1

  公开（公告）日：2011-01-26
• [EN] TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS<br/>[FR] COMPOSES DE TETRAHYDROISOQUINOLINE POUR LE TRAITEMENT DE TROUBLES DU SYSTEME NERVEUX CENTRAL
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2006066197A1

  公开（公告）日：2006-06-22

  [EN] Certain tetrahydroisoquinoline compounds are histamine H₃ receptor and serotonin transporter modulators useful in the treatment of histamine H₃ receptor-and serotonin-mediated diseases.
  [FR] Certains composés de tetrahydroisoquinoline sont un récepteur d'histamine H₃ et des modulateurs du transporteur de sérotonine utiles dans le traitement de maladies à médiation du récepteur d'histamine H₃ et à médiation de sérotonine.
• WO2006/66197
  申请人：——

  公开号：——

  公开（公告）日：——
• Two Analogues of Fenarimol Show Curative Activity in an Experimental Model of Chagas Disease
  作者：Martine Keenan、Jason H. Chaplin、Paul W. Alexander、Michael J. Abbott、Wayne M. Best、Andrea Khong、Adriana Botero、Catherine Perez、Scott Cornwall、R. Andrew Thompson、Karen L. White、David M. Shackleford、Maria Koltun、Francis C. K. Chiu、Julia Morizzi、Eileen Ryan、Michael Campbell、Thomas W. von Geldern、Ivan Scandale、Eric Chatelain、Susan A. Charman

  DOI：10.1021/jm401610c

  日期：2013.12.27

  Chagas disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), is an increasing threat to global health. Available medicines were introduced over 40 years ago, have undesirable side effects, and give equivocal results of cure in the chronic stage of the disease. We report the development of two compounds, 6 and (S)-7, with PCR-confirmed curative activity in a mouse model of established T. cruzi infection after once daily oral dosing for 20 days at 20 mg/kg 6 and 10 mg/kg (S)-7. Compounds 6 and (S)-7 have potent in vitro activity, are noncytotoxic, show no adverse effects in vivo following repeat dosing, are prepared by a short synthetic route, and have druglike properties suitable for preclinical development.